Back to the journal
Peptides
5 min read
Updated Oct 29, 2026.
Short answer. On Oct 28, 2026, HHS said it does not intend to take enforcement action against licensed pharmacies, federal facilities or licensed physicians that compound six peptides, BPC-157 included, when every condition is met [1][2]. That is enforcement discretion. Nothing got approved by FDA. Nothing went on the 503A bulks list. The policy is interim [1][2]. As of Oct 29, 2026.
Part of The Sommar Peptide Guide. Your group chat says peptides are legal now. For six of them, a narrow version of that is true, with conditions.
What changed
HHS filed the "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" for public inspection on Oct 28, 2026 [1][3]. Docket HHS-OASH-2026-0496. FR Doc 2026-22192 [1].
The core is one line. HHS does not intend to act against a covered compounder that makes one of six peptides and meets every requirement [1][2].
Before this, all six sat in limbo. FDA took them off its Category 2 safety-risk list in Apr 2026 [5]. In Jul 2026 its advisory committee voted to recommend each one for the 503A bulks list [4]. That vote was advisory and changed nothing by itself [4].
The six peptides
Peptide | Form | Routes |
|---|---|---|
Acetate | Under the skin, into muscle, oral, topical | |
Acetate | Under the skin or into muscle | |
Acetate | Under the skin or into muscle | |
Acetate | Under the skin or into muscle, in intermittent courses | |
Free base | Nasal | |
Acetate | Topical or oral |
Source: the policy's Appendix A and Appendix B [1]. Each peptide comes in one named form, with set routes. A product has to use the ingredient Appendix A names [2].
These are the same six the FDA advisory committee voted for in July 2026 [4].
Who is covered
The policy names these compounders [1]:
A state-licensed pharmacy
A federal facility
A licensed physician
Outsourcing facilities, the 503B kind, are not named [1][2]. Anyone else is outside the policy. That includes the website selling vials as "research use only."
What it does NOT mean
No FDA approval. Compounded drugs are not FDA approved. This policy approves nothing [1][2].
No 503A listing. No peptide was added to the 503A bulks list [1][2].
Interim. It lasts while the 503A bulks list is built through rulemaking, until a final rule addresses each peptide [1].
Revisable. It is not binding. HHS may revisit it, in whole or in part, if a safety signal or a quality problem shows up [1].
HHS's call. The policy is framed as HHS's. It does not state FDA's own position [1][2].
Six only. Every other peptide keeps its prior status. Ipamorelin, CJC-1295, GHK-Cu, Selank, DSIP and the rest did not move [1]. Are Peptides Legal? covers where each one stands.
The conditions
Per the FDA Law Blog's summary of the policy [2]:
One active ingredient per product, from Appendix A. No blends.
A registered source. The bulk ingredient comes from an FDA-registered maker that follows good manufacturing practice. The maker's location goes on the certificate of analysis. Testing follows Appendix B.
One kind of syringe. The only syringe that may come packaged with it is one FDA cleared through 510(k).
Reporting. Compounders report products, serious side effects and quality problems to FDA through MedWatch, and to states.
A required label. It reads "This is a compounded drug product. Not for resale."
Miss one, and the policy does not apply [1].
What happens next
When | What |
|---|---|
Oct 30, 2026 | Scheduled to publish in the Federal Register [1] |
2 weeks from publication | Public comment window [1] |
Later | FDA rulemaking on the 503A bulks list [1] |
That rulemaking "may propose adding some or all of these peptides to the 503A bulks list" [1]. Read the word "may" twice. Nothing in the policy promises a final listing.
What to watch out for
"Research use only" sellers are not covered. The policy reaches licensed pharmacies, federal facilities and licensed physicians [1]. A site shipping vials labeled not for human use is none of those.
Compounded products only come from licensed pharmacies or physicians. A covered product carries the compounded-drug label above [2]. No licensed compounder and no label means the policy does not reach it.
Blends are out. One active ingredient per product [2].
Other peptides are out. A peptide with a similar story online is still outside the six. Check the table.
For how compounding works and why the 503A list matters, start with The Sommar Peptide Guide.
Peptide waitlist
Want an email when a peptide's FDA or HHS status changes? Join the peptide waitlist. Email updates only. Sommar Club does not offer, prescribe or sell any of these six.
FAQ
Is BPC-157 legal now? HHS says it does not intend to act against licensed pharmacies, federal facilities or licensed physicians that compound BPC-157 acetate under the policy's conditions [1][2]. It is still not approved by FDA and not on the 503A bulks list, as of Oct 29, 2026 [1].
Are these six peptides FDA approved now? No. The policy approves nothing, and compounded drugs are not FDA approved [1][2].
Does the policy cover ipamorelin, CJC-1295 or GHK-Cu? No. It covers six peptides only. Every other peptide keeps its prior status [1].
Is this permanent? No. It is interim and not binding. It runs until rulemaking on the 503A list addresses each peptide, and HHS may revisit it if a safety or quality problem shows up [1].
Sources
HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Docket HHS-OASH-2026-0496, FR Doc 2026-22192 (filed for public inspection Oct 28, 2026). https://public-inspection.federalregister.gov/2026-22192.pdf
FDA Law Blog (Hyman, Phelps & McNamara). The PEPTIDE-L Wave Reaches HHS: Enforcement Discretion … Not the Finish Line (Oct 28, 2026). https://www.thefdalawblog.com/2026/10/the-peptide-l-wave-reaches-hhs-enforcement-discretion-not-the-finish-line/
The Hill. Report on the HHS peptide compounding policy (Oct 28, 2026). https://thehill.com/policy/healthcare/6178382-hhs-peptides-compounding-pharmacies-maha-agenda/
Bass Berry. FDA Advisory Committee Recommends Six Peptides for Compounding (Jul 31, 2026). https://bassberry.com/news/fda-advisory-committee-recommends-six-peptides-for-compounding-what-the-evaluation-criteria-tell-us-about-the-road-ahead/
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of Apr 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Sommar Club does not prescribe or sell BPC-157, TB-500, MOTS-c, Epitalon, Semax or KPV. This page is for education only. It is not medical or legal advice. Policies change; check the as-of date.
